EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Perspective: Making Treatment Decisions for Crohn’s Disease in 2025—Key Considerations

Mario Andrea Latorre, Michael Rennie, Konstantina Rosiou iD, Christian Philipp Selinger iD

Journal of Clinical Medicine · 28.09.2025 · 14 (19) · 6879

DOI: 10.3390/jcm14196879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.09.2025. Verfasst von Mario Andrea Latorre und 3 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment algorithm for Crohn’s disease evolves over time. In this review article we highlight nine studies from the last decade that have influenced our thinking on the treatment of Crohn’s disease. This perspective is a narrative, opinion-based review and reflects our personal thinking on some aspects of the treatment of Crohn’s disease. We selected original studies that have influenced our thoughts on luminal Crohn’s disease treatment significantly. Moderate to severe Crohn’s disease should be treated appropriately from diagnosis with advanced therapy or surgery in select cases of limited ileal disease. Close observation may be sufficient for mild cases. Small intra-abdominal abscesses can be treated without surgery in some cases and a cooperative multi-disciplinary team working approach with radiology, surgery and dietitians is key. Anti-TNF therapy provides effective and relatively inexpensive first-line treatment but requires careful therapeutic monitoring and/or immunomodulator co-therapy to avoid immunogenicity. Those achieving remission at 1 year very often maintain this long-term. For those experiencing non-response or loss of response to anti-TNF therapy, ustekinumab or risankizumab offer appropriate second-line treatments. Biomarkers to better guide treatment decisions are urgently needed. Dietary approaches to the management of Crohn’s disease are currently evolving and may provide a future disease-modifying avenue.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseaseimproved careinflammatory bowel disease

Autor:innen und Institutionen

  • Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.
  • Department of Internal Medicine and Medical Therapeutics, University of Pavia, 27100 Pavia, Italy.

ORCID-Profile: Konstantina Rosiou, Christian Philipp Selinger

Zitieren

APA

Latorre, M. A., Rennie, M., Rosiou, K., & Selinger, C. P. (2025). Perspective: Making Treatment Decisions for Crohn’s Disease in 2025—Key Considerations. Journal of Clinical Medicine, 14(19), 6879. https://doi.org/10.3390/jcm14196879

Vancouver

Latorre MA, Rennie M, Rosiou K, Selinger CP. Perspective: Making Treatment Decisions for Crohn’s Disease in 2025—Key Considerations. Journal of Clinical Medicine. 2025;14(19):6879. doi:10.3390/jcm14196879

BibTeX
@article{Latorre2025,
  author = {Latorre, Mario Andrea and Rennie, Michael and Rosiou, Konstantina and Selinger, Christian Philipp},
  title = {Perspective: Making Treatment Decisions for Crohn’s Disease in 2025—Key Considerations},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {19},
  pages = {6879},
  doi = {10.3390/jcm14196879}
}
Kostenlos starten →